JP6669774B2 - 筋萎縮の治療に有用な誘導体 - Google Patents

筋萎縮の治療に有用な誘導体 Download PDF

Info

Publication number
JP6669774B2
JP6669774B2 JP2017554365A JP2017554365A JP6669774B2 JP 6669774 B2 JP6669774 B2 JP 6669774B2 JP 2017554365 A JP2017554365 A JP 2017554365A JP 2017554365 A JP2017554365 A JP 2017554365A JP 6669774 B2 JP6669774 B2 JP 6669774B2
Authority
JP
Japan
Prior art keywords
group
muscle
acid
dichlorophenyl
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017554365A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018513162A5 (cg-RX-API-DMAC7.html
JP2018513162A (ja
Inventor
ソフィ， エヌ． レイナル，
ソフィ， エヌ． レイナル，
ミシュリーヌ， エール． ケルゴー，
ミシュリーヌ， エール． ケルゴー，
ヴァレリ オーティエ，
ヴァレリ オーティエ，
クリスティーヌ， ジェ． シャロン，
クリスティーヌ， ジェ． シャロン，
ジャン−ドゥニ デュラン，
ジャン−ドゥニ デュラン，
フランク， エフ． レピフル，
フランク， エフ． レピフル，
アニック， エム． オーデ，
アニック， エム． オーデ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabrain Research
Original Assignee
Metabrain Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabrain Research filed Critical Metabrain Research
Publication of JP2018513162A publication Critical patent/JP2018513162A/ja
Publication of JP2018513162A5 publication Critical patent/JP2018513162A5/ja
Application granted granted Critical
Publication of JP6669774B2 publication Critical patent/JP6669774B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2017554365A 2015-04-16 2016-04-14 筋萎縮の治療に有用な誘導体 Active JP6669774B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1553410 2015-04-16
FR1553410A FR3035105A1 (fr) 2015-04-16 2015-04-16 Derives utiles dans le traitement de l'atrophie musculaire
PCT/FR2016/050864 WO2016166480A1 (fr) 2015-04-16 2016-04-14 Dérives utiles dans le traitement de l'atrophie musculaire

Publications (3)

Publication Number Publication Date
JP2018513162A JP2018513162A (ja) 2018-05-24
JP2018513162A5 JP2018513162A5 (cg-RX-API-DMAC7.html) 2018-10-18
JP6669774B2 true JP6669774B2 (ja) 2020-03-25

Family

ID=53758355

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017554365A Active JP6669774B2 (ja) 2015-04-16 2016-04-14 筋萎縮の治療に有用な誘導体

Country Status (13)

Country Link
US (1) US10350184B2 (cg-RX-API-DMAC7.html)
EP (1) EP3283064B1 (cg-RX-API-DMAC7.html)
JP (1) JP6669774B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170137201A (cg-RX-API-DMAC7.html)
CN (1) CN107735082B (cg-RX-API-DMAC7.html)
CA (1) CA2988625A1 (cg-RX-API-DMAC7.html)
DK (1) DK3283064T3 (cg-RX-API-DMAC7.html)
ES (1) ES2741012T3 (cg-RX-API-DMAC7.html)
FR (1) FR3035105A1 (cg-RX-API-DMAC7.html)
PL (1) PL3283064T3 (cg-RX-API-DMAC7.html)
PT (1) PT3283064T (cg-RX-API-DMAC7.html)
RU (1) RU2715553C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016166480A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3055548B1 (fr) * 2016-09-05 2018-09-28 Metabrain Research Utilisation de metabolites du tryptophane dans le traitement de l'atrophie musculaire
FR3078252B1 (fr) * 2018-02-28 2020-08-14 Biophytis Phytoecdysones pour leur utilisation dans la prevention de la perte de force musculaire lors d’une immobilisation
CN111253246B (zh) * 2020-03-16 2023-03-17 中国医学科学院基础医学研究所 酰基酸类衍生物及其制备方法和医药用途
CN114533731B (zh) * 2022-02-25 2024-06-04 上海大学 一种氨基吡啶衍生物在制备肌肉萎缩抑制剂中的应用
CN117205215B (zh) * 2023-11-08 2024-01-26 广州喜鹊医药有限公司 川芎嗪硝酮衍生物在制备预防或治疗肌少症药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2204406A1 (en) * 1972-10-26 1974-05-24 Delalande Sa 1-Phenyl-3-aminocarbonylpropan-1-one oxime carbamates - with analgesic, antiinflammatory, hypotensive and sedative activities etc.
WO1998009940A1 (en) * 1996-09-04 1998-03-12 Warner-Lambert Company Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
US6541521B1 (en) * 1999-07-12 2003-04-01 Warner-Lambert Company Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases
PT1268407E (pt) * 2000-03-20 2004-11-30 N Gene Res Lab Inc Derivados de amidoxima de acido propenocarboxilico, um processo para a sua preparacao e composicoes farmaceuticas contendo os mesmos
SI1945632T1 (sl) * 2005-11-08 2014-03-31 Vertex Pharmaceuticals Incorporated Heterocikliäśni modulatorji za prenaĺ alce z atp-vezavno kaseto
US20110230428A1 (en) * 2008-07-22 2011-09-22 John Wityak Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2017044551A1 (en) * 2015-09-11 2017-03-16 Mitobridge, Inc. Ppar-alpha agonists for treating mitochondrial diseases

Also Published As

Publication number Publication date
CA2988625A1 (en) 2016-10-20
CN107735082B (zh) 2021-07-27
ES2741012T3 (es) 2020-02-07
EP3283064B1 (fr) 2019-05-08
US20180303780A1 (en) 2018-10-25
RU2017139915A (ru) 2019-05-17
US10350184B2 (en) 2019-07-16
DK3283064T3 (da) 2019-08-12
WO2016166480A1 (fr) 2016-10-20
PL3283064T3 (pl) 2019-12-31
PT3283064T (pt) 2019-08-21
FR3035105A1 (fr) 2016-10-21
RU2017139915A3 (cg-RX-API-DMAC7.html) 2019-06-06
KR20170137201A (ko) 2017-12-12
JP2018513162A (ja) 2018-05-24
EP3283064A1 (fr) 2018-02-21
RU2715553C2 (ru) 2020-03-02
CN107735082A (zh) 2018-02-23

Similar Documents

Publication Publication Date Title
JP6669774B2 (ja) 筋萎縮の治療に有用な誘導体
JP5461197B2 (ja) 代謝障害を処置するための組成物および方法
US20230129598A1 (en) Methods of treating estrogen receptor-associated diseases
US20140193906A1 (en) Screening methods for spinal muscular atrophy
WO2012028233A1 (de) Imidazo [4,5-c]chinoline als dna-pk-inhibitoren
US9938315B2 (en) Chemical compounds and use thereof for improving muscular quality
KR20220029681A (ko) 특발성 폐 섬유증의 치료 방법
CN102112131A (zh) 治疗地中海贫血的方法
JP5980812B2 (ja) Ｐａｓｋの阻害のための複素環化合物
US20190030079A1 (en) Composition for inducing beige adipocyte differentiation containing exosome derived from stem cells
JP6694452B2 (ja) トリアゾール誘導体およびｐｄｅ４活性化体としてその使用
WO2012000632A1 (de) Pyrazolochinoline
US20230037225A1 (en) SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS APELIN RECEPTOR AGONISTS
JP6847946B2 (ja) イン・ビボ生着能増強用５−ヒドロキシトリプタミン１ｂ受容体刺激剤
KR20190121285A (ko) 근위축증 치료를 위한 트립토판 대사산물의 용도
US20140107153A1 (en) Therapeutic quinoline and naphthalene derivatives
JP6791977B2 (ja) 骨格筋の肥大剤としてのフロスタン−３オール誘導体
JP2014506868A (ja) フラボノイド配糖体による神経発生の刺激
US10689394B2 (en) Thieno[2,3-b]pyridine derivative, quinoline derivative, and use thereof
RU2806346C2 (ru) Использование метаболитов триптофана для лечения мышечной атрофии
EP2229361A1 (en) Tetrahydroindoles having sphingosine-1-phosphate receptor activity
JPH10330258A (ja) 好酸球活性化抑制剤
HK1238578A1 (en) Methods of inhibiting muscle atrophy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180906

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190415

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20190508

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20190725

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190730

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200117

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200227

R150 Certificate of patent or registration of utility model

Ref document number: 6669774

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250